跳至主要内容
临床试验/EUCTR2011-006234-16-IT
EUCTR2011-006234-16-IT进行中(未招募)不适用

Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refractory to conventional therapies

ISTITUTO NAZIONALE PER LA CURA TUMORI0 个研究点开始时间: 2012年3月5日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Histopathologic diagnosis of neuroendocrine tumour; TC or MRI scan within 3 months from enrollment; Nuclear medicine imaging showing an high expression of somatostatin receptors; ECOG performance status equal or lower than 2; Age over 18 years old; Measurableor evaluable disease; Adequate medullar reserve and renal functionality; Signed informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 50

排除标准

  • Concomitant non neoplastc serious diseases not adequately controlled; Pregnancy or lactation; Surgery or radiotherapy within two weeks from beginning of treatment

研究者

发起方
ISTITUTO NAZIONALE PER LA CURA TUMORI

相似试验